[ad_1]
The university notes that so far all work is proceeding smoothly and quickly. Phase I clinical trials in humans began in April. More than 1,000 vaccines have been performed and the subjects are still being monitored.
Up to 10,260 adults and children will be invited to participate in the next phase of the study, and other scientific and medical research institutions in the UK will assist the University of Oxford in this phase of the study.
In Phase II of the studies, it is planned to expand the age range of the study subjects: groups of 56-69 patients older than 70 years and from 5 to 12 years will be distinguished. The immune response to the vaccine in these individuals will be evaluated and the immune response of younger and older individuals to the vaccine will be explained.
A large number of people over the age of 18 will be offered to participate in phase III clinical trials. The goal of this part of the study will be to determine how well the vaccine protects against COVID-19.
The study vaccine, whose working name is ChAdOx1 nCoV-19, was developed using a virus (ChAdOx1), which is an attenuated version of the adenovirus of the common cold. This virus is capable of causing symptoms of a runny nose in chimpanzees, but it has been genetically modified so that it cannot reproduce in humans.
Group Leader Oxford Vaccine prof. Andrew Pollard said: “Clinical trials are well advanced and we are now launching studies to assess how well the vaccine elicits an immune response in the elderly and to see if it can provide protection against the disease in a broader population. We are very grateful to volunteers for their support in helping determine if the new vaccine can protect people from the pandemic coronavirus. “
Sarah Gilbert, Professor of Vacology at the Jenner Institute (UK), said: “The COVID-19 vaccine research team has worked hard to assess the safety and immunogenicity of ChAdOx1 nCoV-19 and has done preparatory work to assess the effectiveness of the vaccine.This vaccine is already of great interest to people over 55 who were not invited to participate in Phase I studies, so now we can include older patients in the vaccine evaluation. investigations in the broader territory of the country. “
[ad_2]
